Forma Life Sciences, which inherited BioDuro’s California production operations earlier this year, has officially ...
Galderma has significantly raised its peak annual sales estimate for Nemluvio (nemolizumab) to more than $4 billion | Galderma has doubled its peak annual sales estimate for Nemluvio (nemolizumab) to ...
After delivering solid sales growth in a difficult 2025, Germany’s Merck KGaA may have a tougher go of things this year, which the company is crediting in part to a predicted onslaught of U.S.
Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. | Leo Pharma has decided “It’s GO time” for the launch of its JAK inhibitor cream Anzupgo. Having built its ...
Vanda Pharmaceuticals’ seven-year ambition to score a coveted label expansion for sleep drug Hetlioz has taken an unusual turn, with the FDA acquiescing to a formal hearing on the matter. | The ...
About four years after the case was filed—and against the backdrop of a significantly changed COVID-19 vaccine ...
Not long after Novo Nordisk received an untitled letter from the FDA disputing certain elements of the first TV spot for its ...
Collegium Pharmaceutical has tapped an appropriately glitzy star as the face of a new campaign spotlighting the bright side of life with attention-deficit/hyperactivity disorder (ADHD). | Collegium ...
The FDA is taking no prisoners as it continues its efforts to combat widespread GLP-1 drug compounding. | In the letters sent to 30 different telehealth companies that market compounded versions of ...
One of the most powerful voices in the biopharma industry, Pfizer CEO Albert Bourla, Ph.D., has weighed in with sharp ...
With a substantial manufacturing base already locked down in China, CRDMO BioDuro is taking a short jaunt down to Taiwan for its latest drug ingredients production play. | BioDuro, headquartered in ...
Sanofi is betting $1.53 billion on a novel drug from Sino Biopharmaceutical, securing global rights to a first-in-class JAK/ROCK inhibitor that could play a double role in the French pharma’s ...
Results that may be inaccessible to you are currently showing.
Hide inaccessible results